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ABSTRACT
Seronegative spondyloarthropathies are a group of diseases characterized by several clinical features 
such as inflammatory back pain, sacroiliac joint inflammation, and the presence of the HLA B27 antigen, 
which occurs more frequently than the general population. Non-specific bowel inflammation, skin lesions, 
particularly psoriasis or uveitis, are also typical in patients or their family members [1]. In many situations, 
clinical progression of spondyloarthropathies can be assessed by imaging of the sacroiliac joints [2, 
3]. SAPHO syndrome (Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis), is a rare disease, classified 
as seronegative spondyloarthropathy due to many typical clinical features for this group of diseases. A 
large variety of symptoms and atypical clinical picture of SAPHO syndrome causes significant diagnostic 
difficulties [3, 4]. Presented here is a case report of a 41-year-old male patient with a twenty-year history 
of the disease. Initially, his disease took the form of chronic, recurrent multifocal osteomyelitis (CRMO), 
which finally turned into a spondyloarthropathy that met the classification criteria for ankylosing spondylitis.
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INTRODUCTION
SAPHO syndrome is a rare clinical syndrome with 
co-occurrence of synovitis, skin lesions such as acne, 
palmoplantar pustulosis (PPP), excessive bone forma-
tion and osteomyelitis. According to current knowledge, 
it is not possible to clearly determine the pathogenetic 
mechanisms of the disease. Environmental factors, 
e.g. infections (most often Propionibacterium acnes),
or a genetic predisposition, have been considered
[2, 4]. The inclusion of SAPHO syndrome into spondy-
loarthropathies is supported by the presence of sac-
roiliitis, vertebral osteomyelitis, discitis, psoriasis and
inflammatory bowel diseases that occur more frequently 
than in the general population, similarly to the presence 
of HLA B27 antigen, which occurs in about 30% of
cases [2–4]. According to some authors, there are two 
subtypes of SAPHO syndrome, one of which is a form of 
spondyloarthropathy coexisting with hyperostosis and 
skin lesions, mostly with morphology of palmo-plantar 
pustulosis or pustular psoriasis [2]. This form is dom-
inated by symptoms of arthritis in the anterior chest 
wall and inflammation of the sternocostal joints [2, 5]. 
Inflammatory changes also often occur in the sacroiliac 
joints, spinal joints and/or intervertebral discs as well 
as in of hands and feet joints, often asymmetrically 
[1, 2, 5]. The other type presents with chronic, recurrent, 
multifocal inflammation of the bone and bone marrow 
(CRMO), also defined as CNO (chronic, non-bacterial 
osteomyelitis) [2, 6]. This syndrome, until recently, has 
been mainly observed in children and young adults, 
and is characterized by recurring inflammation of the 
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bones and/or bone marrow, especially in the epiphyses 
of long bones (femur and tibia), intervertebral discs, 
collarbones, mandible and the pelvis [7–9].
The diagnostic criteria of SAPHO syndrome were 
presented in 1994 by Kahn (Tab.1). Meeting one of the 
proposed criteria is necessary in order to diagnose the 
syndrome [7, 10].
SAPHO syndrome diagnosis is difficult due to the 
frequently atypical clinical picture, the occurrence of 
different symptoms at various stages of the disease, 
and the lack of a specific biomarker. However, specific 
changes are often found in imaging studies [4]. The 
most frequently observed laboratory abnormalities are 
elevated ESR and CRP or increased activity of alkaline 
phosphatase [2].
In imaging studies, subchondral bone sclerosis may 
be observed, as well as erosions in the anterior chest 
wall joints, sometimes with periosteal inflammation. 
Pericostal ossification and hyperostosis are frequent 
phenomena, particularly in the collarbone area, as well 
as osteosclerosis of bone bodies, osteophytosis and 
syndesmophytes in the thoracic and lumbosacral spine 
[2, 5]. Inflammation of the sacroiliac joints occurs in 
about 35% of the cases. [3, 7] Inflammation of interver-
tebral discs is found in about 25–35% of patients and is 
also part of the spine changes related to the disease.
Imaging is very helpful for SAPHO syndrome 
diagnosis and differentiation between the observed 
structural changes. Classical radiography, computed 
tomography, scintigraphy and magnetic resonance 
(especially in early stages of the disease) are used. 
Histopathological tests are essential to determine the 
nature of bone tissue changes [5, 8, 10].
Differential diagnostics is based, mainly, on the ex-
clusion of an underlying infection of the bones and/or 
bone marrow, proliferative processes, or histiocytosis 
[2, 5]. In the diagnosis of SAPHO syndrome, it has be-
come crucial to consider diseases such as ankylosing 
spondylitis, psoriatic arthritis or arthritis accompanying 
inflammatory bowel diseases. All of these conditions are 
characterized by the similarities of symptoms, as well 
as a potential evolution of the clinical picture during the 
course of the disease [2, 3].
This paper discusses the case of a 41-year-old 
male patient with a long-term history of osteomyelitis 
symptoms and inflammation of the intervertebral discs, 
in whom symptoms of spondyloarthropathy developed 
over the last twenty years of the disease. The patient on 
admission to the Rheumatology Ward, fulfilled the Amer-
ican College of Rheumatology (ACR) modified New York 
criteria of ankylosing spondylitis, established in1988.
Case description
We presented the case of a 41-year-old male patient 
with a history of recurrent episodes of inflammation of 
the body and left ramus of the mandible, occurring 
since the age of 19. Inflammation of intervertebral discs 
and progressive, multilevel ossification of the thoracic 
and lumbar spine segments was observed in the sub-
sequent years. He was admitted to the Rheumatology 
Ward with significantly increased pain in the spine and 
hip joints, which remained constant despite the time 
of day, physical activity, and experienced long-lasting 
morning stiffness. He had no history of comorbidities, 
and no significant family history for any diseases, im-
portant for further diagnosis. His multiannual history 
required retrospective analysis of medical records 
provided, concerning the years between 1992 and 
2013. The occurrence of inflammation of the mandible, 
which appeared between 1992 and 1995, and affected 
the body and the left mandible ramus, was described 
there. During several hospital admissions to the dental 
surgery clinic, laboratory tests showed only a slight 
elevation in inflammatory markers. X-ray of the mandible 
was described as: “several osteolytic foci and necroses 
within the body and the left mandibular ramus”. Histo-
pathological assessment in 1995 (during the third year 
of the disease), corresponded to chronic inflammation 
of the bone with possible complications related to 
fibrous dysplasia; intertrabecular bone remodelling, 
multiplication of fibrous tissue and vast inflammatory 
infiltrations were also described. Multiple antibiotic ther-
apies (including lincomycin, vancomycin, tobramycin, 
pefloxacin, sulfamethoxazole with trimethoprim, oxacil-
lin, amoxicillin with clavulanic acid), and non-steroidal 
anti-inflammatory drugs (NSAIDs) were administered to 
this patient several times between 1992 and 1995. In 
the subsequent years, no recurrences of the inflam-
matory changes of the jaw bone were observed. He 
had his teeth extracted on multiple occasions due to 
advanced decay.
Table 1. Diagnostic criteria of SAPHO syndrome 
according to Kahn [7, 10]
Chronic and recurring inflammations of bone and bone 
marrow (CRMO/CNO)
•  Usually aseptic (seldom propionibacterium acne in PCR)
•  with the involvement of the spine and peripheral bones
•  with or without skin lesions 
Aseptic, acute or chronic arthritis coexisting with:
• pustular psoriasis of hands and feet (PPP)
• hidradenitis
• acne (conglobata, ulcerans) 
Each inflammation of bones and marrow coexisting with :
• pustular psoriasis of hands and feet (PPP)
• hidradenitis
• acne (conglobata, ulcerans)
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Back pain, without typical symptoms of inflamma-
tion, as well as progressive limitation of thoracic spine 
mobility, became dominant in the clinical picture since 
2006, which forced the patient to take NSAID that 
exceeded the maximum doses. This led to recurring 
erosive gastritis with mild anaemia, in subsequent 
years. MRI tests showed hyperintense areas of the end 
plates of TH12-L5 bodies in the T-1 and T2-weighted 
images that, according to the description, “correspond 
to Scheuermann’s disease or bone fragility due to met-
abolic reasons”.
Owing to the suspicion of a proliferative disease, 
the patient was extensively examined, including un-
dergoing a bone marrow histopathological assessment 
in the oncology dept., where the neoplastic disease 
was excluded.
Due to the increasing pain and further reduction 
in the spine mobility after the subsequent 7 months, 
the patient was admitted in the rheumatology ward. 
There, the progression of thoracic spine changes in 
the MRI with uneven contours of the end-plates and 
losses at the levels of Th10/Th11/Th12 were found. 
Compression of Th12 body with marginal osteoscle-
rosis and similar, multilevel changes in the lumbar 
part were also described. In the radiologist’s opinion, 
this picture supported an inflammatory background, 
most probably haematogenous. During this time, no 
inflammatory changes in the sacroiliac joints were 
found. Laboratory tests showed ESR 72 mm, CRP 
157mg/l, Hb 10.4 G/dL, and ALP 409 U/L, charac-
teristic for an active inflammatory process. The high 
level of alkaline phosphate was assessed as not 
linked to liver pathology. HLA B27 antigen detection 
and the TST (tuberculin skin test/Mantoux test) were 
negative. Following neurosurgical consultation, the 
patient was transferred to the neurosurgery ward 
with a diagnosis of infectious spondylodiscitis. There, 
antibiotic therapy, subcutaneous administration of 
calcitonin, and a plaster cast corset were applied. 
In subsequent years’ constant spinal pain in the 
thoracic and lumbar areas continued. As well as 
kyphoscoliosis, deterioration of the strength of his 
lower extremities occurred.
In 2010, subsequent MRI of the thoracic spine 
described: “…there is most probable an inflammatory 
mass surrounding the vertebral bodies from the front and 
lateral side with a 12 mm thick muff along the thoracic 
spine, penetrating and surrounding the costovertebral 
joints and transverse processes, there is an inflammatory 
infiltration in the epidural space, the spinal cord is com-
pressed” showing the progression of the inflammatory 
changes and risk of occurrence of neurological symp-
toms resulting from the compression of the spinal cord. 
This, alongside consistently elevated ESR, prompted 
subsequent antibiotic therapy. 
Spastic paresis of the muscles occurred in this pa-
tient in 2013. A multilevel laminectomy procedure was 
performed in the neuro-orthopaedics dept. Intraoper-
ative biopsy and inflammatory tissue culture were per-
formed during the procedure and revealed no bacterial 
growth. The subsequent MRI showed vast ossification of 
the majority of motion segments in the cervical, thoracic 
and lumbar spine. This clinical picture was deemed as 
a consequence of advanced ankylosing spondylitis or 
vast, chronic, infectious inflammatory changes. During 
hospitalization, SPECT (single-photon emission com-
puted tomography) examination was performed, and 
accumulation of a marker in the thoracic spine, heel 
bones, pelvis and the sacroiliac joints were observed. 
There was no clinical improvement in subsequent 
months, despite daily treatment with NSAID (400 mg 
of ketoprofen), and 400 mg of tramadol. Increasing 
pain and decreased mobility of the lumbosacral spine 
and pelvis resulted in the patient becoming wheelchair 
bound. He returned to the rheumatology ward in April 
2014. 
Physical examination showed intense pain and 
multidimensional limitation of mobility in the thoracic 
and lumbosacral spine, as well as in the hip joints. Tests 
assessing the sacroiliac joints were uninterpretable due 
to hip joints involvement. There were no inflammatory 
symptoms in other peripheral joints. During the physical 
examination, no cutaneous or nail lesions, no digestive 
tract involvement symptoms, as well as any other signif-
icant findings, were observed. Numerous abnormalities 
were found in laboratory tests: ESR 58 mm/h, CRP 
81.8 mg/L, ALP 772 U/L, Hb 12.8 g/dL, hypergamma-
globulinemia, with no presence of monoclonal protein, 
low 25OHD concentration (25-hydroxy-vitamin D), 
decreased urinary calcium excretion, increased type 
1 C-terminal telopeptide and osteocalcin, increased 
testosterone concentration, normal concentration of 
the parathyroid hormone. Rheumatoid factor and an-
ti-citrullinated peptide antibodies, as well as anti-nuclear 
antibodies, were absent. The Quantiferon Gold test and 
Brucella antibodies were negative.
In the X-ray of the spine (Fig. 1), multilevel syn-
desmophytes (picture of a “bamboo spine”) in the 
thoracic and lumbosacral sections of the spine were 
demonstrated, in addition to lesions related to the 
laminectomy. Pelvis X-ray (Pic.2) showed remodelling 
of the bone structure, uneven surfaces of the femoral 
heads, protrusion, and significant bilateral hip joint 
space narrowing. In the sacroiliac joints, narrowed, 
blurred and uneven joint spaces with subchondral bone 
sclerosis were found. 
MRI of the pelvis revealed narrowing and blurred 
sacroiliac joint spaces (mainly in the lower part of the 
joint), with periarticular bone marrow oedema in the 
sacrum and ilium, which was enhanced with contrast 
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Figure 1. Changes in the spine of the „bamboo spine” type (arrows)
Figure 2. Inflammatory changes in the sacroiliac joints 
(arrows). Inflammatory changes in the pelvis (ring)
administration. Additionally, bilateral deepening of 
the acetabulum, with the femoral head bulging into 
the small pelvis were described. Bilateral deforma-
tion of the head and neck of the femur and bone 
remodelling were also found. Also described were 
reduced signal from the pelvic cartilage with bone 
ankylosis, effusion in the periarticular bursae and sy-
novial overgrowth. The clinical picture corresponded 
to the ankylosing spondylitis accompanied by hip 
joint inflammation.
The full doses of NSAID, opioid analgesics, includ-
ing buprenorphine, myorelaxants were implemented. 
Vitamin D3 supplementation was also applied. BASDAI 
(Bath Ankylosing Spondylitis Activity Score) index was 
scored as 5.8. The spine pain VAS (Visual Analogue 
Scale) was scored as 76 mm.
After supplementing vitamin D deficiency, the patient 
was administered intravenous infusion of 90 mg Pamid-
ronate. However, the patient refused continuation of 
this treatment due to lower extremity pain and malaise.
During treatment, clinically significant improvement 
was not observed. Follow-up BASDAI after monthly 
therapy according to the above schedule was scored 
8.9, and pain of the spine VAS was checked as 90 mm.
According to the observed activity of the disease and 
risk of complete loss of hip structures, treatment with 
an anti-TNF-alpha drug was started. The patient was 
administered with 50 mg of golimumab, and a significant 
reduction in the symptoms of the inflammatory disease 
was achieved within 3-months. During the regular as-
sessments of the therapy course, there were a reduction 
in ESR values, CRP concentration and improvement in 
BASDAI and VAS values of spinal pain (Tab.2).
During anti-TNF-alpha therapy, no side effects were 
observed. Treatment was stopped due to low disease 
activity in the 18th month. However, after about 8 weeks 
the patient suffered from a recurrence disease activity 
symptoms (shown by the highlighted line in Table 2.). 
An improvement in laboratory parameters was achieved 
and low disease activity was observed after therapy with 
golimumab restarting on the 23rd week of treatment. 
Discussion
Diagnosis of seronegative spondyloarthropathy, ac-
cording to the criteria of ASAS (Assessment of Spondy-
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Table 2. List of assessments of the disease activity in subsequent months of anti-TNF- alpha therapy. Highlighted the 
line of the table presents the assessment after the treatment with golimumab discontinuation
Month of therapy ESR CRP VAS of the spine pain BASDAI 
3 4 mm/h 9.4 mg/L 60 mm 3.40 
6 5 mm/h 4.2 mg/L 30 mm 3.10 
18 2 mm/h 6.5 mg/L 15 mm 2.20 
20 59 mm/h 121 mg/L 80 mm 6.60 
23 8 mm/h 9.5 g/dL 10 mm 1.40 
loArthritis International Society) from 2010 is possible on 
the basis of the typical clinical symptoms, co-occurring 
with (often discrete) imaging changes, or the presence 
of HLA B27 antigen [2, 3]. Many symptoms typically 
related to spondyloarthropathies, such as the spine 
joints or the sacroiliac joints inflammation, coexisting 
psoriasis or the inflammatory bowel disease, justify 
the classification of SAPHO syndrome into this group 
[2]. Similarly, like many other spondyloarthropathies, 
SAPHO syndrome can also evolve in its course. Chang-
es in the involved joints, develop over the years. In 
some cases, the patient initially diagnosed as SAPHO 
syndrome, during the course of the disease, fulfil the 
modified New York diagnostic criteria for ankylosing 
spondylitis, or classification criteria of CASPAR (Clas-
sification Criteria for Psoriatic Arthritis) [3, 11].
SAPHO syndrome is a rare disease, and often its 
atypical course, “stretching over the time” of particular 
symptoms, as well as a lack of specific biomarkers 
of the disease, makes the correct diagnosis difficult 
to establish. According to related publications, there 
is often a long diagnostic delay for cases of SAPHO 
syndrome [4, 7]. Diagnostic difficulties may particu-
larly refer to cases which run as chronic, recurring (in 
many cases recurrences can be easily overlooked), 
multifocal osteomyelitis (CRMO). Vertebral bodies 
and the intervertebral discs or, as in this case, the 
mandible, are frequent locations of the inflammatory 
changes. An acute course of the disease often pres-
ents with inflammation of intervertebral discs, which 
can lead to a significant deterioration in the patient’s 
mobility, especially, if there are complications, such as 
spinal cord compression [6]. Laboratory abnormalities 
accompanying the disease, and the observed imaging 
changes may suggest a developing proliferative pro-
cess or infectious etiology. As a result, it often causes 
complex, time- and cost-consuming diagnostics being 
performed, or exposes patients to long-term antibiotic 
therapy. [12–14]. 
In the present state of knowledge, there are no uni-
form SAPHO syndrome treatment recommendations 
developed [15]. NSAIDs are commonly used and in 
many cases are effective as the disease course is 
often a relatively mild. In many situations, particularly 
with coexisting skin lesions, antibiotics, for example, 
azithromycin or doxycycline are used in therapy. Dis-
ease-modifying antirheumatic drugs (DMARDs), such 
as methotrexate or sulfasalazine are also useful in 
cases when the disease manifests in peripheral joints, 
however, information on their effectiveness varies 
[14, 15]. Many bisphosphonate studies demonstrate 
good results of such therapy, but they are rather limited 
to reduce the extent of bone changes. In publications, 
intravenous administration of pamidronate in doses 
between 30 to 90 mg is most frequently described with 
positive results reported [16]. Glucocorticosteroids 
play a relatively insignificant role, similarly to other 
spondyloarthropathies. Their application is limited to 
local or oral administration in acute presentations 
of the disease [17]. In recent years there have been 
some publications discussing the positive effects of 
SAPHO syndrome therapy with  anti-TNF-alpha agents 
[18, 19]. Most frequently, publications describing 
positive results with this group refer to Infliximab, ad-
ministered in a typical for spondyloarthropathies dose, 
5 mg/kg of body weight at 0, 2 and 6 weeks [19, 20]. 
Unfortunately, along with increased use of TNF-alpha 
inhibitors for SAPHO syndrome, there are a number of 
the publications revealing an increased risk of exac-
erbation of skin manifestations, which suggests their 
distinctness from osteoarticular symptoms [21]. 
Conclusions
Presented case is an example of the SAPHO syn-
drome, commencing with typical CRMO symptoms 
which, over time evolving into seronegative spondyloar-
thropathy, in the course of which the clinical symptoms 
and advanced imaging changes allow diagnose of 
disease as ankylosing spondylitis. Symptoms of the 
mandible and intervertebral disc inflammation required 
the exclusion of a proliferative process or an infectious 
disease. Repeated, with no positive result antibiotic 
therapy is characteristic in the history of this patient, 
similarly to other cases described. Special emphasis 
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should be put on the fact of non-occurrence of psoriasis 
or above-mentioned skin lesions, which often coexist 
with SAPHO syndrome, the absence of symptoms of 
other diseases, such as inflammatory bowel disease 
or uveal diseases, in the patient as well as in his family 
history. The absence of HLA B27 antigen in this patient, 
despite various symptoms of ankylosing spondylitis, is 
also worth mentioning. 
In this case, the decision to administer TNF-alpha 
inhibitor was a result of the disease evolution to the 
typical clinical picture of ankylosing spondylitis. In-
volvement of the hips, which could result in a complete 
destruction of these joints’ structures, as well as the 
total ineffectiveness of the initial treatment, predisposed 
patient to a risk of permanent disability. Observing the 
clinical response to golimumab administration, and 
particularly the rapid recurrence of the symptoms after 
the therapy interruption, which is commonly observed 
during therapy of spondyloarthropathies with anti-TNF 
alfa agents, seem to confirm, that this case describes 
an evolution of typical SAPHO syndrome to ankylosing 
spondylitis. 
Disclosure of interest: Authors report no 
competing interests
Abbreviations
ACR — American College of Rheumatology 
ALP — alkaline phosphatase
ASAS — Assessment of Spondyloarthritis International 
Society
BASDAI — Bath Ankylosing Spondylitis Activity Score 
CASPAR — Classification Criteria for Psoriatic Arthritis
CNO — chronic, non-bacterial osteomyelitis
CRMO — chronic, recurrent multifocal osteomyelitis 
CRP — C-reactive protein
ESR — erythrocyte sedimantation rate
Hb — hemoglobin
HLA B27 — Human Leukocyte Antigen B27
MRI — magnetic renosance imaging
NSAIDs — non-steroidal anti-inflammatory drugs 
PCR — polymerase chain reaction
PPP — palmo-plantar pustulosis 
SAPHO — Synovitis, Acne, Pustulosis, Hyperostosis, 
Osteitis
SPECT — single-photon emission computed tomog-
raphy
TNF alpha — tumor necrosis factor alpha
TST — tuberculin skin test
VAS — Visual Analogue Scale
References
1. Nguyen MT, Borchers A, Selmi C, et al. The SAPHO syndrome. 
Semin Arthritis Rheum. 2012; 42(3): 254–265, doi: 10.1016/j.semar-
thrit.2012.05.006, indexed in Pubmed: 23153960.
2. Przepiera-Będzak H, Brzosko M, Brzosko I. Zespół SAPHO. Pol Arch 
Med Wewn. 2004; 111(2): 265–8.
3. Van Mechelen M, Lories RJ. Microtrauma: no longer to be ignored in 
spondyloarthritis? Curr Opin Rheumatol. 2016; 28(2): 176–180, doi: 
10.1097/BOR.0000000000000254, indexed in Pubmed: 26751839.
4. Van Doornum S, Barraclough D, McColl G, et al. SAPHO: rare or 
just not recognized? Semin Arthritis Rheum. 2000; 30(1): 70–77, doi: 
10.1053/sarh.2000.8371, indexed in Pubmed: 10966214.
5. Schilling F. [SAPHO syndrome: clinico-rheumatologic and radiologic 
differentiation and classification of a patient sample of 86 cases]. 
Z Rheumatol. 2000; 59(1): 1–28, indexed in Pubmed: 10769419.
6. Kubaszewski Ł, Wojdasiewicz P, Rożek M, et al. Syndromes with 
chronic non-bacterial osteomyelitis in the spine. Reumatologia. 2015; 
53(6): 328–336, doi: 10.5114/reum.2015.57639, indexed in Pubmed: 
27407266.
7. Kahn MF, Khan MA. The SAPHO syndrome. Baillieres Clin Rheumatol. 
1994; 8(2): 333–362, indexed in Pubmed: 8076391.
8. Fleuridas G, Teysseres N, Ragot JP, et al. [Diffuse sclerosing oste-
omyelitis of the mandible and SAPHO syndrome]. Rev Stomatol Chir 
Maxillofac. 2002; 103(2): 96–104, indexed in Pubmed: 11997737.
9. Kahn MF, Hayem F, Hayem G, et al. Is diffuse sclerosing osteomyelitis 
of the mandible part of the synovitis, acne, pustulosis, hyperostosis, 
osteitis (SAPHO) syndrome? Analysis of seven cases. Oral Surg Oral 
Med Oral Pathol. 1994; 78(5): 594–598, indexed in Pubmed: 7838465.
10. Zielińska A, Rupiński R, Filipowicz-Sosnowska A. Zespół SAPHO 
– odmienność przebiegu – trudności diagnostyczne. Reumatologia. 
2006; 44: 213–219.
11. Dumolard A. Gaudin Ph. Sapho syndrome or psoriatic arthritis? Rheu-
matology. 1998; 38: 463–7.
12. Olivieri I, Padula A, Palazzi C. Pharmacological management of SAPHO 
syndrome. Expert Opin Investig Drugs. 2006; 15(10): 1229–1233, 
doi: 10.1517/13543784.15.10.1229 , indexed in Pubmed: 16989598.
13. Rukavina I. SAPHO syndrome: a review. J Child Orthop. 2015; 9(1): 19–
27, doi: 10.1007/s11832-014-0627-7, indexed in Pubmed: 25585872.
14. Govoni M, Colina M, Massara A, et al. „SAPHO syndrome and 
infections”. Autoimmun Rev. 2009; 8(3): 256–259, doi: 10.1016/j.
autrev.2008.07.030, indexed in Pubmed: 18721907.
15. Özen M, Kalyoncu U. SAPHO syndrome may be treated effectively with 
combined drug regimens - A case report. International Journal of Case 
Reports and Images. 2011; 2(1): 8, doi: 10.5348/ijcri-2011-01-14-cr-2.
16. Courtney PA, Hosking DJ, Fairbairn KJ, et al. Treatment of SAPHO 
with pamidronate. Rheumatology (Oxford). 2002; 41(10): 1196–1198, 
indexed in Pubmed: 12364646.
17. Delattre E, Guillot X, Godfrin-Valnet M, et al. SAPHO syndrome 
treatment with intravenous pamidronate. Retrospective study of 22 
patients. Joint Bone Spine. 2014; 81(5): 456–458, doi: 10.1016/j.
jbspin.2014.01.017, indexed in Pubmed: 24561020.
18. Wagner AD, Andresen J, Jendro MC, et al. Sustained response to 
tumor necrosis factor alpha-blocking agents in two patients with 
SAPHO syndrome. Arthritis Rheum. 2002; 46(7): 1965–1968, doi: 
10.1002/art.10539, indexed in Pubmed: 12124882.
19. Ben Abdelghani K, Dran DG, Gottenberg JE, et al. Tumor necrosis factor-
-alpha blockers in SAPHO syndrome. J Rheumatol. 2010; 37(8): 1699–
1704, doi: 10.3899/jrheum.091086, indexed in Pubmed: 20472920.
20. Hayem G, Ben M’, Toussirot E, et al. SAPHO syndrome treated by 
TNF alpha-blocking agents: report of 45 cases. Arthritis Rheum. 
2010; 62: S2269.
21. Baeten D, van Hagen PM. Use of TNF blockers and other targeted 
therapies in rare refractory immune-mediated inflammatory diseases: 
evidence-based or rational? Ann Rheum Dis. 2010; 69(12): 2067–2073, 
doi: 10.1136/ard.2009.126813, indexed in Pubmed: 20705637.
